Abstract
Angiotensin-converting enzyme 2 (ACE2) is an enzymatically active homologue of angiotensin-converting enzyme that degrades angiotensin I, angiotensin II, and other peptides. Recent studies have shown that under pathologic conditions, ACE2 expression in the kidney is altered. In this review, we briefly summarize recent studies dealing with pharmacologic interventions that modulate ACE2 expression. ACE2 amplification may have a potential therapeutic role for kidney disease and hypertension.
MeSH terms
-
Angiotensin I / biosynthesis*
-
Angiotensin I / drug effects
-
Angiotensin II / biosynthesis*
-
Angiotensin II / drug effects
-
Angiotensin II Type 1 Receptor Blockers / therapeutic use
-
Angiotensin-Converting Enzyme 2
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
Antihypertensive Agents / therapeutic use
-
Disease Progression
-
Humans
-
Hypertension / complications
-
Hypertension / drug therapy*
-
Peptidyl-Dipeptidase A / biosynthesis*
-
Peptidyl-Dipeptidase A / drug effects*
-
Receptor, Angiotensin, Type 1 / drug effects
-
Renin-Angiotensin System / drug effects
Substances
-
Angiotensin II Type 1 Receptor Blockers
-
Angiotensin-Converting Enzyme Inhibitors
-
Antihypertensive Agents
-
Receptor, Angiotensin, Type 1
-
Angiotensin II
-
Angiotensin I
-
Peptidyl-Dipeptidase A
-
ACE2 protein, human
-
Angiotensin-Converting Enzyme 2